0947 GMT - Fevertree's near-term development remains tough to make out amid a tie-up with beer giant Molson Coors, Berenberg's Karl Burns writes. The U.K. maker of tonics and mixers for alcohol has suffered from diminished enthusiasm for gin and tonic in its home country and by on-trade pressure too, Burns notes. A deal with Molson Coors, which last year agreed to acquire Fevertree distribution rights in the U.S., offers a boost but visibility remains low at this point, he says. "We believe the investment case hinges on a successful execution of the Molson Coors distribution deal," Burns says. Berenberg has a hold rating and a 920 pence target on the stock; shares gain 0.2% to 972 pence. (joshua.kirby@wsj.com; @joshualeokirby)

(END) Dow Jones Newswires

February 16, 2026 04:51 ET (09:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.